Overview
The marketing authorisation for Nobilis Influenza H5N6 has been withdrawn at the request of the marketing authorisation holder.
Nobilis Influenza H5N6 : EPAR - Summary for the public
English (EN) (250.46 KB - PDF)
български (BG) (452.82 KB - PDF)
español (ES) (251.36 KB - PDF)
čeština (CS) (395.47 KB - PDF)
dansk (DA) (253.18 KB - PDF)
Deutsch (DE) (252.07 KB - PDF)
eesti keel (ET) (249.87 KB - PDF)
ελληνικά (EL) (425.06 KB - PDF)
français (FR) (252.5 KB - PDF)
italiano (IT) (251.82 KB - PDF)
latviešu valoda (LV) (399.57 KB - PDF)
lietuvių kalba (LT) (372.2 KB - PDF)
magyar (HU) (386.96 KB - PDF)
Malti (MT) (430.75 KB - PDF)
Nederlands (NL) (251.43 KB - PDF)
polski (PL) (405.82 KB - PDF)
português (PT) (252.06 KB - PDF)
română (RO) (364.4 KB - PDF)
slovenčina (SK) (393.59 KB - PDF)
slovenščina (SL) (382.11 KB - PDF)
Suomi (FI) (251.3 KB - PDF)
svenska (SV) (251.65 KB - PDF)
Product information
Nobilis Influenza H5N6 : EPAR - Product Information
English (EN) (364.64 KB - PDF)
български (BG) (548.1 KB - PDF)
español (ES) (308.34 KB - PDF)
čeština (CS) (461.05 KB - PDF)
dansk (DA) (312.43 KB - PDF)
Deutsch (DE) (324.63 KB - PDF)
eesti keel (ET) (352.16 KB - PDF)
ελληνικά (EL) (544.01 KB - PDF)
français (FR) (356.33 KB - PDF)
italiano (IT) (367.12 KB - PDF)
latviešu valoda (LV) (492.49 KB - PDF)
lietuvių kalba (LT) (432.59 KB - PDF)
magyar (HU) (446.67 KB - PDF)
Malti (MT) (472.75 KB - PDF)
Nederlands (NL) (358.08 KB - PDF)
polski (PL) (486.2 KB - PDF)
português (PT) (355.11 KB - PDF)
română (RO) (461.08 KB - PDF)
slovenčina (SK) (470.62 KB - PDF)
slovenščina (SL) (453.77 KB - PDF)
Suomi (FI) (352.05 KB - PDF)
svenska (SV) (363.69 KB - PDF)
Latest procedure affecting product information: S/0001
05/07/2010
Nobilis Influenza H5N6 : EPAR - All Authorised presentations
English (EN) (262.39 KB - PDF)
български (BG) (325.44 KB - PDF)
español (ES) (259.28 KB - PDF)
čeština (CS) (318.17 KB - PDF)
dansk (DA) (258.53 KB - PDF)
Deutsch (DE) (224.61 KB - PDF)
eesti keel (ET) (260.75 KB - PDF)
ελληνικά (EL) (318.83 KB - PDF)
français (FR) (257.04 KB - PDF)
italiano (IT) (255.4 KB - PDF)
latviešu valoda (LV) (318.29 KB - PDF)
lietuvių kalba (LT) (289.19 KB - PDF)
magyar (HU) (312.31 KB - PDF)
Malti (MT) (318.49 KB - PDF)
Nederlands (NL) (262.76 KB - PDF)
polski (PL) (312.76 KB - PDF)
português (PT) (260.9 KB - PDF)
română (RO) (291.22 KB - PDF)
slovenčina (SK) (319.14 KB - PDF)
slovenščina (SL) (307.79 KB - PDF)
Suomi (FI) (257.28 KB - PDF)
svenska (SV) (258.04 KB - PDF)
Product details
- Name of medicine
- Nobilis Influenza H5N6
- Active substance
- inactivated whole avian influenza virus antigen of H5 subtype (strain H5N6, A/duck/Potsdam/2243/84)
- International non-proprietary name (INN) or common name
- adjuvanted inactivated vaccine against avian influenza virus type A, subtype H5
- Species
- Chicken
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QI01AA23
Pharmacotherapeutic group
Immunologicals for avesTherapeutic indication
For active immunisation of chickens against avian influenza type A, subtype H5.
Reduction of clinical signs, mortality and excretion of virus after challenge with a virulent H5N1 strain, were shown by two weeks after a single dose vaccination.
Serum antibodies have been shown to persist in chickens for at least 7 months and studies performed with other vaccine strains show that serum antibodies would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine.
Authorisation details
- EMA product number
- EMEA/V/C/000125
Accelerated assessment
This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.
Exceptional circumstances
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.
- Marketing authorisation holder
- Intervet International BV
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands - Marketing authorisation issued
- 31/01/2008
- Revision
- 1
Assessment history
Nobilis Influenza H5N6 : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (224.44 KB - PDF)